The Drugs Controller General of India (DCGI) is likely to approve the COVID-19 vaccine of Zydus Cadila this week, making it the sixth vaccine to be approved in India.
Zydus Cadila had on July 1 announced that it had applied for emergency use authorisation (EUA) of its ZyCoV-D three-dose COVID-19 vaccine.
The Subject Expert Committee (SEC) of DCGI is likely to approve the vaccine this week, news agency ANI reported on Monday citing sources.
ZyCoV-D is a DNA plasmid vaccine, which uses a portion of the genetic code — DNA or RNA — in the virus to stimulate an immune response. The company had conducted clinical trials for the vaccine in over 50 centres across the country, including in the adolescent population in the 12-18 years age group.
Last week, the Centre gave EUA to Johnson and Johnson’s (J&J) unit Janssen’s single-dose COVID-19 vaccine. Serum Institute of India’s Covishield, Bharat Biotech’s Covaxin, Russia’s Sputnik V and Moderna Inc’s vaccine are the other COVID-19 vaccines approved in India.
India has so far administered over 50.86 crore vaccine doses as part of the nationwide COVID-19 vaccination programme.